PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures

Titre officiel

A Phase III Multi-centre Open-label Randomized Controlled Trial of Multi-parametric Magnetic Resonance Imaging (MRI)-Targeted Biopsy Compared to Systematic Trans-rectal Ultrasound (TRUS) Guided Biopsy

Sommaire:

Cette étude vise à évaluer l’efficacité de la biopsie ciblée par IRM par rapport à la technique de référence, c’est-à-dire la biopsie systématique guidée par ETR, pour le dépistage du cancer de la prostate significatif et non significatif sur le plan clinique chez les hommes sans antécédents de biopsie. Le remplacement de la biopsie ciblée par IRM par la biopsie systématique guidée par ETR à titre de technique de référence pour le diagnostic du cancer de la prostate est une répercussion possible de cet essai.

Description de l'essai

Primary Outcome:

  • MRI-The proportion of men with clinically significant cancer (Gleason > 7)
Secondary Outcome:
  • Biopsy-The proportion of men with clinically significant cancer (Gleason ≥7)
  • Proportion of men in each arm with clinically insignificant cancer
  • Proportion of men in each arm with Gleason >4+3 detected.
  • Proportion of men in MRI arm who avoid biopsy.
  • Proportion of men in the MRI arm whom the PI-RADS score for suspicion of clinically significant cancer was 3, 4 or 5 but no clinically significant cancer was detected.
  • Proportion of men in each arm who go on to definitive local treatment (e.g. radical prostatectomy, radiation therapy, brachytherapy) or systemic treatment (e.g. hormone therapy, chemotherapy).
The standard pathway for prostate cancer diagnosis is trans-rectal ultrasound guided (TRUS) biopsy of the prostate following an elevated PSA. TRUS guidance is performed primarily for anatomic guidance as the ultrasound poorly discriminates between cancerous and non-cancerous tissue. TRUS guided prostate biopsies are concentrated in areas of the peripheral zone, thought to harbor the majority of cancer. An alternative pathway for prostate cancer diagnosis in men with elevated PSA is to perform multi-parametric magnetic resonance imaging (MPMRI) to localize cancer. This information is used to direct a subsequent biopsy, known as an MRI-targeted biopsy. MRI-targeted biopsy has been shown in preliminary studies to detect a similar or greater amount of clinically significant cancer than systematic TRUS guided biopsy and has several other potential advantages including: the ability to differentiate between clinically significant and insignificant cancer, reducing unnecessary biopsy and fewer numbers of biopsy cores, reducing biopsy-related side-effects. A 'clinically insignificant cancer' is cancer that is unlikely to progress or to affect an individual's life expectancy and therefore does not warrant treatment. However when diagnosed with low grade cancer that is likely to be insignificant, a large proportion of subjects request treatment in case a more significant cancer is present. A challenge in this area is that subjects are typically not aware that their cancer is clinically insignificant, and often view the early diagnosis and aggressive treatment they have been subjected to as life-saving. A prostate cancer detection procedure that differentiates clinically significant cancer from clinically insignificant cancer is therefore a major unmet need. The potential implications of this trial include:
  • A redefinition of the prostate cancer diagnostic pathway;
  • A reduction in the number of subjects undergoing prostate biopsy;
  • A reduction in the number of biopsy cores taken per subject;
  • A reduction in biopsy-related adverse events including sepsis and pain;
  • A reduction in the over-diagnosis of clinically insignificant prostate cancer;
  • A reduction in the economic burden of diagnosing and treating prostate cancer.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer